Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome

Abstract

Purpose:

To compare the effect of topical application of tacrolimus 0.03% eyedrops versus cyclosporine 0.05% in Sjogren syndrome subjects with severe dry eyes.

Design:

A prospective single-blinded simply randomized controlled study.

Methodology:

60 Sjogren patients were randomized into

Group A: 30 patients were instructed to put tacrolimus 0.03% eyedrops in one eye for 6 months and placebo eyedrops in the other eye, (N = 30, 44.9 ± 12.58 years).

Group B: 30 patients were instructed to put cyclosporine 0.05% eyedrops in one eye for 6 months and placebo eyedrops in the other eye (N = 30, 49.4 ± 12.92 years).

Main outcome measures: Patients were evaluated at day 0, 90, and 180 for Ocular Surface Disease Index Questionnaire (OSDI), frequency of use of artificial tears, average fluorescein tear break up time (TBUT), ocular surface staining scores, Schirmer I test, meibum quality, and expressibility scores.

Results:

Upon comparing both eyedrops, the mean value of OSDI decrease was 38.25 ± 18.29% versus 31.69 ± 18.57% (p-value 0.09), SICCA score decrease was 2.97 ± 1.92 versus 2.27 ± 2.02 (p-value 0.124) the decrease in artificial tear substitute use was 3.90 ± 2.22 versus 3.63 ± 1.92 (p-value 0.616), increase in Schirmer I values were 4.10 ± 4.21 and 4.26 ± 2.00 (p-value 0.590) in eyes treated with tacrolimus and cyclosporine respectively. Neither of them affected meibum quality or expressibility scores.

Conclusion:

Both tacrolimus and cyclosporine significantly improved patient symptoms, frequency of artificial tears use and ocular surface staining compared to placebo-controlled eyes. However, no significant difference regarding the efficacy of both eyedrops at the end of 6 months treatment of severe dry eyes of Sjögren syndrome patients.

Trial registration:

ClinicalTrials.gov. Identifier: NCT03865888.

Keywords

Drug delivery systems/pharmacokinetics cornea/external disease tear deficiency states immunology ocular surface agents pharmacology

Get full access to this article

View all access options for this article.

References

Thompson

Isenberg

Jury

, et al. Exploring BAFF: its expression, receptors, and contribution to the immunopathogenesis of Sjogren’s syndrome. Rheumatology 2016; 55: 1548–1555.

Wolffsohn

JS.

Arita

Chalmers

, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf 2017; 15: 539–574.

Samarkos

Moutsopoulos

. Recent advances in the management of ocular complications of Sjogren’s syndrome. Curr Allergy Asthma Rep 2005; 5: 327–332.

Pflugfelder

Geerling

Kinoshita

, et al. DEWS Management, and therapy management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007; 5: 163–178.

McCabe

Narayanan

Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry 2009; 80: 555–566.

Donnenfeld

Pflugfelder

S C

. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009; 54: 321–338.

Jones

Downie

Korb

, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15: 575–628.

Takeuchi

Okuyama

Konno

, et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Transplant Proc 2005; 37: 1745–1747.

Yuan

Zhai

Huang

, et al. Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation. J Ocul Pharmacol Ther 2012; 28: 153–158.

10.

Vitali

Bombardieri

Jonsson

, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

11.

Schiffman

Christianson

Jacobsen

, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000; 118: 615–621.

12.

Smith

Nichols

Baldwin

, et al. Current patterns in the use of diagnostic tests in dry eye evaluation. Cornea 2008; 27: 656–662.

13.

Whitcher

Shiboski

, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren’s syndrome international registry. Am J Ophthalmol 2010; 149: 405–415.

14.

Van Bijsterveld

. Diagnostic tests in the sicca syndrome. Arch Ophthalmol 1969; 82: 10–14.

15.

Bron

Abelson

Ousler

, et al. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 108–152.

16.

Bron

Benjamin

Snibson

. Meibomian gland disease. Classification and grading of lid changes. Eye 1991; 5: 395–411.

17.

Shimazaki

Goto

Ono

, et al. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology 1998; 105: 1485–1488.

18.

Salib

McDonald

Smolek

. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileuses. J Cataract Refract Surg 2006; 32: 772–778.

19.

Willen

McGwin

Liu

, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens 2008; 34: 43–45.

20.

Altiparmak

Acar

Ozer

, et al. Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients. Eye 2010; 24: 1044–1050.

21.

Rao

SN.

Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther 2010; 26: 157–164.

22.

Perry

Barsam

, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. Cornea 2011; 30: 1098–1104.

23.

Schrell

Cursiefen

Kruse

, et al. Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca. Klin Monbl Augenheilkd 2012; 229: 548–53.

24.

Sacchetti

Mantelli

Lambiase

, et al. Systematic review of randomized clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014; 98(8): 1016–1022.

25.

Wan

Chen

Young

. Efficacy and safety of topical 0.05% cyclosporine eye drop in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf 2015; 13(3): 213–225.

26.

Moscovici

Holzchuh

Chiacchio

, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012; 31: 945–949.

27.

Moscovici

Holzchuh

Sakassegawa-Naves

, et al. Treatment of Sjogren’s syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study. Cont Lens Anterior Eye 2015; 38: 373–378.

28.

Kharbanda

Walia

Singh

, et al. Efficacy of tacrolimus 0. 03 % eye ointment in the treatment of chronic ocular surface inflammation in severe dry eye. J Dent Med Sci 2016; 15: 40–43.

29.

Fatima

Chaurasia

Singh

. Section : pharmacology evaluation of the effects of 0. 03 % tacrolimus on Schirmer tear test and tear film break-up time in patients of chronic dry eye disease section. Pharmacology 2018; 5: 9–13.

30.

Kim

Lee

, et al. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. Int J Ophthalmol 2018; 11(4): 593–600.

31.

Perry

Doshi-Carnevale

Donnenfeld

, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006; 25(2): 171–175.

32.

Sakassegawa-Naves

Ricci

HMM

Moscovici

, et al. Tacrolimus ointment for refractory posterior blepharitis. Curr Eye Res 2017; 42: 1440–1444.